The significance of soluble HLA-G plasma levels as well as messenger HLA-G for B-cell chronic lymphocytic leukemia (B-CLL).

[Guest guest]

The significance of soluble HLA-G plasma levels as well as messenger HLA-G for

B-cell chronic lymphocytic leukemia (B-CLL).

K Giannopoulos, M Schmitt, M Kowal, P Wlasiuk, A Bojarska-Junak, J Rolinski, and

A Dmoszynska

Leuk Res, May 20, 2008; .

Clinical Immunology Department, Medical University of Lublin, 20950 Lublin,

Poland; Department of Internal Medicine III, University of Ulm, 89081 Ulm,

Germany.

The immunosuppression accompanies B-cell chronic lymphocytic leukemia (B-CLL)

but might be also responsible for disease progression by enabling CLL cells to

escape from the immunosurveillance. Some particles involved in the regulation of

an immune system might represent prognostic value for B-CLL. Recently we found

no correlation between HLA-G on messenger and protein level, suggesting that

HLA-G is released in soluble form. To confront this hypothesis we characterized

soluble HLA-G (sHLA-G) by the prognostic factors in the first cohort of 34 CLL

patients. No correlation was observed between sHLA-G levels in ZAP-70(+) and

ZAP-70(-) CLL as well as in CD38(+) CLL and CD38(-) CLL patients. Next, we

wondered whether gene expression of HLA-G, which represent the whole HLA-G pool

in the cell, posses prognostic value for CLL. In the second cohort of 41 CLL

patients we assessed messenger levels of HLA-G by the strongest prognostic

factors in CLL including cytogenetics, IgVH mutational status, ZAP-70 as well as

CD38. No changes of HLA-G expression levels were found in different CLL groups

characterized by IgVH gene mutational status, ZAP-70 as well as CD38. We

observed no differences in expression of HLA-G in various cytogenetic groups of

CLL including del17p, del13q, del11q, +8q, +3q, del14q and del6q when compared

to those with normal karyotype or with 12+. Both, mRNA expression of HLA-G and

levels of its soluble form in plasma bring no additional prognostic value for

B-CLL patients.

PMID: 18499249